Nomlabofusp, Placebo to Nomlabofusp
CLIN-1601-301
Phase 3 small_molecule active
Quick answer
Nomlabofusp, Placebo to Nomlabofusp for Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85. is a Phase 3 program (small_molecule) at Larimar Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Larimar Therapeutics
- Indication
- Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active